67199-57-9

Usage

Uses

Used in Fragrance and Flavor Industry:
2,3-Dihydro-4-methoxy-1H-inden-1-ol is used as a key ingredient in the fragrance and flavor industry for its distinctive woody and floral scent. It contributes to the creation of complex and appealing scents in various products.
Used in Perfume Production:
In the perfume industry, 2,3-Dihydro-4-methoxy-1H-inden-1-ol is used as a fixative agent to enhance the longevity and depth of perfumes. Its pleasant aroma adds a unique character to the fragrances, making them more appealing to consumers.
Used in Soap and Personal Care Products:
2,3-Dihydro-4-methoxy-1H-inden-1-ol is used as a fragrance component in soaps and other personal care products. Its woody and floral scent provides a refreshing and pleasant experience for users, enhancing the overall sensory appeal of these products.
Used in Antioxidant Applications:
Due to its potential antioxidant properties, 2,3-Dihydro-4-methoxy-1H-inden-1-ol can be used in various consumer products to prevent oxidation and extend the shelf life. This makes it a valuable additive in the food and beverage industry, as well as in cosmetic and pharmaceutical products.
Used in Antimicrobial Applications:
The antimicrobial properties of 2,3-Dihydro-4-methoxy-1H-inden-1-ol make it suitable for use in products that require preservation and prevention of microbial growth. It can be incorporated into cleaning products, personal care items, and even medical devices to ensure hygiene and safety.
Used in Consumer Product Manufacturing:
2,3-Dihydro-4-methoxy-1H-inden-1-ol's versatility and valuable properties make it a sought-after component in the manufacturing of various consumer products. Its use extends beyond fragrances and flavors, finding applications in a wide range of industries, from cosmetics and personal care to food and beverages, and even pharmaceuticals.

Upstream product

• 13336-31-7 4-methoxylindanone 
• 40731-98-4 4-hydroxy-2,3-dihydroindan-1-one 
• 119-84-6 C₆H₄(CH₂CH₂C(O)O) 

Downstream Products

• 1613055-20-1 C₄₅H₅₂N₆O₄ 
• 1613055-38-1 C₃₀H₃₁F₄N₃O₅S 
• 1613055-45-0 C₄₅H₅₀F₂N₆O₄ 
• 1613055-52-9 C₅₁H₆₈N₈O₆ 
• 1613055-61-0 C₃₂H₃₅F₃N₄O₆S 
• 1613083-77-4 C₅₀H₅₈N₈O₆ 
• 1613055-67-6 C₃₀H₃₀F₅N₃O₅S 
• 1613055-72-3 C₄₅H₄₈F₄N₆O₄ 
• 1613055-82-5 C₃₁H₃₄F₃N₃O₅S 
• 1613055-85-8 C₄₇H₅₆N₆O₄ 
• 1613055-91-6 C₃₁H₃₄F₃N₃O₅S 
• 1613055-92-7 C₄₇H₅₆N₆O₄ 
• 1613055-98-3 C₃₂H₃₆F₃N₃O₅S 
• 1613056-01-1 C₄₉H₆₀N₆O₄ 

Relevant academic research and scientific papers

Kinetic resolution of racemic benzofused alcohols catalysed by HMFO variants in presence of natural deep eutectic solvents

5-Hydroxymethylfurfural oxidase (HMFO) has demonstrated to be a useful biocatalyst for the selective oxidation of alcohols employing oxygen as mild oxidant with no requirement of expensive organic cofactors. This wild-type HMFO biocatalyst and an engineered thermostable variant have been tested in the kinetic resolution of different benzofused alcohols. The use of natural deep eutectic solvents was also explored in HMFO-catalysed oxidation of alcohols. The oxidation of racemic 1-indanol showed a higher conversion and selectivity in presence of 60% v/v of different NADES, especially for those containing carbohydrates. By choosing properly the biocatalyst and the NADES, good enantioselectivity values can be obtained, demonstrating the advantages of employing these neoteric solvents in biocatalysed processes.

HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS

The present technology provides compounds according to Formula (I) as well as compositions including such compounds useful for the treatment of cancers such as non-small cell lung cancer, bladder cancer, or colon cancer.

BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF

The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases.

FUSED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X', Y, Y', A, A',Q1, Q2, R1-R4, X4, R5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof, which can also be used for treating HCV infection or a HCV disorder.

Novel 2-imidazoles as potent and selective α1A adrenoceptor partial agonists

Novel 2-imidazoles have been identified as potent partial agonists of the α1A adrenergic receptor, with good selectivity over the α1B, α1D and α2A receptor sub-types. Sulfonamide 23 possessed attractive drug-like properties with respect to physicochemical and ADME properties and wide ligand selectivity.

Synthesis of Benzo-Fused 1-Azabicyclo[m.n.0]alkanes via the Schmidt Reaction: A Formal Synthesis of Gephyrotoxin

The intramolecular capture of benzocyclobutyl, benzocyclopentyl, and benzocyclohexyl carbocations 7 by azides produces spirocyclic aminodiazonium ions 8, which undergo 1,2-C-to-N rearrangement with loss of dinitrogen to produce benzo-fused iminium ions resulting from either aryl (9) or alkyl (10) migration to the electron-deficient nitrogen atom. Reduction of the iminium ions affords regioisomeric benzo-fused 1-azabicyclo[m.n.0]alkanes, e.g., benzopyrrolizidines, benzoindolizidines, benzoquinolizidines, or perhydrobenzo[f]pyrrolo[1,2-α]azepines in two regioisomeric versions, anilines (e.g., 11-14) and benzylic amines (e.g., 15-18), the result of aryl and alkyl migrations, respectively. Generally, aryl migration is preferred, despite modeling that shows that the lowest energy aminodiazonium ions are those where the departing dinitrogen is preferentially antiperiplanar to the migrating alkyl group rather than the aryl group. The utility of this methodology was illustrated by a formal synthesis of the alkaloid gephyrotoxin 4. A dependence on the efficiency and regioselectivity of the Schmidt reaction upon subtle changes in the structure of the cation precursor was observed, necessitating the exploration of a variety of substrates. Fortunately, these materials were easily made. Ultimately, the azido-alkene 81 bearing a 2-bromoethyl side-chain was useful for the Schmidt reaction, producing the known benzo-fused indolizidine 49, which had been transformed by Ito et al. into gephyrotoxin 4. The synthesis of 49 required nine steps (five purifications) from commercially available 4-methoxy-1-indanone 60 and proceeded in 22% overall yield.

BICYCLIC BENZENOID ALKYLENE AMINO THIENO[3,4-D]ISOTHIAZOLE ETHERS AND THIOETHERS, PHARMACEUTICAL COMPOSITIONS AND USE

A class of bicyclic benzenoid aminoalkylene ether and thioether compounds exhibiting pharmacological activity, including anti-secretory and anti-ulcerogenic activity, pharmaceutical compositions comprising these compounds, and methods for the treatment of gastrointestinal hyperacidity and ulcerogenic disorders in mammals using said compositions.

Bicyclic benzenoid aminoalkylene ethers and thioethers, pharmaceutical compositions and use

A class of bicyclic benzenoid aminoalkylene ether and thioether compounds exhibiting pharmacological activity, including anti-secretory and anti-ulcerogenic activity, pharmaceutical compositions comprising these compounds, and methods for the treatment of gastrointestinal hyperacidity and ulcerogenic disorders in mammals using said compositions.

BICYCLIC BENZENOID AMINOALKYLENE ETHERS AND THIOETHERS, PHARMACEUTICAL COMPOSITIONS AND USE

A class of bicyclic benzenoid aminoalkylene ether and thioether compounds exhibiting pharmacological activity, including anti-secretory and anti-ulcerogenic activity, pharmaceutical compositions comprising these compounds, and methods for the treatment of gastrointestinal hyperacidity and ulcerogenic disorders in mammals using said compositions.